October 28, 2019 10:49 AM EDTUpdated October 29, 07:42 AM

FDA accepts Heron's painkiller re-submission; splits Blueprint Medicines' NDA for avapritinib

Natalie Grover

Reporter

→ Nearly six months ago, Heron was handed an unexpected rejection by the FDA due to manufacturing concerns for HTX-011 — a long-acting non-opioid painkiller …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA accepts Heron's painkiller re-submission; splits Blueprint Medicines' NDA for avapritinib

Natalie Grover

Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA says Ozempic, Wegovy shortage is over

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

FDA ac­cepts Heron's painkiller re-sub­mis­sion; splits Blue­print Med­i­ci­nes' NDA for avapri­tinib

Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

FDA accepts Heron's painkiller re-submission; splits Blueprint Medicines' NDA for avapritinib